NCT05305066Recruiting
Stand UP to Rheumatoid Arthritis (SUPRA)
Innovative Trial Designs, Multi-omics and Advanced Computational Prediction to Transform Clinical Care in RA
Source: ClinicalTrials.gov · Last updated 3 Feb 2026
Brief summary (registry, in English)
Rheumatoid arthritis is a disabling arthritis that affects young women disproportionately. Although the physicians have some excellent treatments, they do not know which treatment is best for which patient. The investigators want to find ways to identify the right drug for the right patient at the right time. This is what personalized medicine is all about.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- First submitted
- 26 Feb 2022
- Start date
- 1 Feb 2023
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Marie Hudson, MD
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT05305066
What you commit to
- Study type: Interventional
- Planned participants: 75
- From 1 Feb 2023 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior b/tsDMARDs for Sub-study 1 or prior b/tsDMARDs other than TNF inhibitors for Sub-study 2;
Other illness
- Contraindication to b/tsDMARD therapy, such as active infection or untreated latent TB, current malignancy, severe organ dysfunction, history of VTE (unless anticoagulated), high risk of cardiovascular disease, pregnancy/lactation;
- Overlap with another inflammatory disease requiring specific immunosuppressive therapy, such as lupus nephritis;
Other
- Unable to provide consent or complete forms (alone or with assistance) in English or French
Who the study is looking for
- Age ≥ 18 years;
- Arthritis that fulfills the 2010 ACR/EULAR classification criteria for RA;
- Failure to standard conventional synthetic DMARDs and eligible for second-line b/tsDMARDs (Sub-study 1) or failure to at least one TNF inhibitor and eligible for third-line b/tsDMARDs (Sub-study 2).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sir Mortimer B Davis - Jewish General Hospital Coordinator of this site? Confirm its status | Montreal | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.